Background: MOG-IgG-associated optic neuritis, encephalitis and myelitis (MONEM) is a recently recognized group of inflammatory central nervous system (CNS) disorders distinct from multiple sclerosis and neuromyelitis optica spectrum disorders. Limited data are available regarding the predictors of relapse in this condition. Objective: We aimed to evaluate the longitudinal serostatus of patients with MOG-IgG and to correlate serostatus with long-term clinical outcomes. Methods: Of 574 consecutive patients who presented with demyelinating inflammatory CNS disorders, we included 31 patients who were MOG-IgG-positive. Patients with MOG-IgG were followed up from 2011 to 2017 at the School of Medicine, University of São Paulo, Brazil. Results: Relapsing disease occurred in 23 out of 31 patients (74%), while 8 (26%) exhibited a monophasic course. All monophasic patients, as well as the majority of relapsing patients, became seronegative during clinical remission. Patients exhibiting disease activity in the last 2 years were more likely to remain positive, with higher medium titres than those found in patients in clinical remission. Conclusion: MOG-IgG patients usually present with a relapsing course, and the risk of relapse was associated with longitudinally persistent MOG-IgG seropositivity. In contrast, patients who experienced a single attack became spontaneously seronegative for MOG-IgG during long-term follow-up.
Introduction
Antibodies against myelin oligodendrocyte glycoprotein (MOG-IgG) have long been associated with central nervous system (CNS) demyelinating disorders, such as aquaporin-4-IgG (AQP4-IgG) seronegative neuromyelitis optica spectrum disorders (NMOSD), multiple sclerosis (MS) and acute demyelinating encephalomyelitis (ADEM). A growing body of evidence suggests that MOG-IgG plays a role in a subgroup of inflammatory demyelinating diseases. [1] [2] [3] [4] [5] However, the clinical phenotype associated with MOG antibodies is variable, and only limited data are available on the initial clinical presentation, most common phenotypes during follow-up and long-term outcomes of affected patients. MOG-IgG-associated optic neuritis, encephalitis and myelitis (MONEM) is a term used to synthesize the most frequent phenotypes associated with MOG-IgG.
The value of longitudinal MOG-IgG analysis remains unknown, but it is reasonable to hypothesize that persistent MOG-IgG is a predictor of a recurrent course in MONEM. If this hypothesis is true, patients with CNS demyelination and positivity for MOG-IgG may require consecutive monitoring of MOG-IgG titres to stratify their risk of new relapses. 5, 6 Hence, longitudinal evaluation may help establish the need for longterm therapy. 5 In this study, we aimed to evaluate longitudinal serum samples obtained from patients with MOG-IgG and to correlate the results with longterm clinical outcomes.
Materials and methods

Patients
Of 574 consecutive patients with demyelinated inflammatory CNS disorders tested for MOG-IgG and AQP4-IgG from 2011 to 2015 at the School of Medicine, University of São Paulo, Brazil, we enrolled all patients who tested positive for MOG-IgG and fulfilled the following clinical criteria: (1) demyelinating disease resembling the NMOSD phenotype according to the International Panel for NMO Diagnosis Criteria 2015 7 and (2) non-MS patients. Available magnetic resonance imaging (MRI) scans were evaluated in a blinded manner by neuroradiologists for NMOSD-like 8 or MS-like lesions. 9 Follow-up Patients were prospectively followed up between 2011 and 2017 through regular visits performed every 6 months. In these visits, the occurrence of relapses and disability were evaluated. The Expanded Disability Status Scale (EDSS) was scored, and visual acuity was assessed using a decimal system and converted to LogMAR for better statistical analysis. All acute attacks were treated with high-dose methylprednisolone, and plasmapheresis was added in patients with severely disabling attacks. The samples were divided into two groups according to relapse: patients with a single attack were included in the monophasic group, and those with two or more attacks were included in the relapsing group. Relapses were defined as new neurological symptoms lasting at least 24 h in the absence of fever or infection. Long-term immunosuppressive therapy was offered to all relapsing patients, while those with a monophasic course did not receive long-term treatment. Clinical remission was defined as the absence of new relapses in the 2 years preceding the last follow-up.
Serum samples
Serum samples were first obtained from all 31 patients at enrolment to detect AQP4-IgG and MOG-IgG. New samples were then regularly obtained at least once a year for longitudinal follow-up. The samples were collected during regular visits in our outpatient clinic and immediately centrifuged and stored at −80°C. Afterwards, the samples were shipped on dry ice to the Brain Institute, Rio Grande do Sul, Brazil, where they were stored at −80°C until analysis.
MOG-IgG antibody and AQP4-IgG assays
All samples were analysed for the presence of MOG-IgG and AQP4-IgG using in-house cell-based assays (CBAs) in live HEK-293 cells, as previously reported. 2, 3 In brief, HEK-293 cells were transiently transfected with a plasmid containing full-length human MOG complementary DNA (cDNA; vector: pIRES2-Dsred2; BD Biosciences, San Jose, CA, USA) using the FUGENE-HD transfection agent (Promega Corp., Madison, WI, USA). Goat anti-human IgG labelled with Fc-specific IgG cross-adsorbed secondary antibody (Pierce Biotechnology, Rockford, IL, USA) was used as the secondary antibody after the transfected cells were exposed to diluted patient serum. The samples were tested for the presence of the MOG antibody and considered positive at a 1:128 dilution. For AQP4-IgG detection, HEK-293 cells were transiently transfected with the M23 isoform of AQP4, and the samples were tested at an antibody dilution of 1:4. The antibody titres from both assays were calculated semi-quantitatively using serial twofold dilutions.
Statistical analysis
Data are expressed as the median and interquartile range (IQR). Nonparametric tests (Mann-Whitney) were used to analyse clinical data among groups, and the Wilcoxon paired test was used to compare data within the same group. Categorical data were analysed with Fisher or chi-square tests, and a p value <0.05 was considered significant. The odds ratio (OR) was used to estimate risk factors for further attacks with a 95% confidence interval (CI). Statistical analyses were performed using IBM-SPSS for Windows version 20.0 (IBM, Armonk, NY, USA) and GraphPad Prism version 7.1 (GraphPad Software, San Diego, CA, USA).
Standard protocol approvals and patient consent
All patients provided written informed consent. The study was approved by the local (CEP) and national ethics committees (CONEP) and conducted according to appropriate Brazilian regulations (approval number: 13434).
Results
MOG-IgG patients: demographic and clinical data
In all, 31 (5.4%) of 574 patients with demyelinated inflammatory idiopathic disease were positive for MOG-IgG. Among these 31 patients, 17 (54.8%) were female and 14 (45.2%) were male, resulting in a female/male ratio of 1.2/1. The median age of symptom onset was 32 years (IQR 24;44).
During follow-up, no patient was positive for AQP4-IgG or received a diagnosis of MS. Only two patients (6.4%) fulfilled the International Panel for NMO Diagnosis Criteria for AQP4-IgG seronegative NMOSD. 7 The most common phenotype at first presentation was optic neuritis (ON; 21/31, 68%), which was followed by myelitis (6/31, 19.4%). The classical association between ON and myelitis at onset was less frequently observed (3/31, 9.6%). The demographic and clinical characteristics of the 31 patients are shown in Table 1 .
MOG-IgG patients: disease activity
Eight out of the 31 included patients (26%) had only one attack, and the remaining 23 patients (74%) exhibited a relapsing course. The median follow-up was 49 months (IQR 34;77) in monophasic patients and 80 months (IQR 38;104) in relapsing patients (p = 0.187). The median time to the second attack was 17 months (IQR 5;48) in the relapsing group, and this was significantly shorter than the follow-up time in the monophasic patients (49 months; IQR 34;77; p = 0.016). In patients with a relapsing course, the median time between attacks was 13.2 months (IQR 6;31), and the median number of attacks was 4 (IQR 2;5.5). Infection prior to the first attack was reported in two patients with monophasic disease, while previous vaccine was described in only one patient with a relapsing course.
The most common attack among the patients was ON (25/31, 80.6%), which was followed by myelitis (13/31, 41.9%). ON was the most frequent form of attack in both the relapsing and the monophasic group. Recurrent ON was found in 14/31 patients (42%) and was associated with a higher number of attacks (4; IQR 2.5;6.5) than other clinical presentations (2; IQR 2;3; p = 0.007). The risk of relapse increased with every new attack of ON (OR 3.66, 95% CI: 1.13-11.85, p = 0.007). The clinical phenotype at onset predicted the presentation of the second attack: patients with ON or myelitis at the time of the first attack had a greater probability of having a relapse in the same CNS area (p = 0.014).
Longitudinally extensive transverse myelitis (LETM) was found in 7 out of 13 (53.8%) of the patients with myelitis. Spinal cord symptoms with a normal spinal MRI was observed in 4/13 (30.8%) of these patients. Imaging and laboratory features of the 31 MOG-IgGpositive patients are shown in Table 2 .
Immunosuppressive therapy
Patients in the monophasic group did not receive longterm immunosuppressive treatment. Of the 23 patients (91%), 21 with a relapsing course received long-term immunosuppressive therapy; the remaining two patients refused immunosuppressive treatment. The median treatment duration was 46 months (IQR 29.5;82.0). Azathioprine was used in 15/21 patients (71.4%), methotrexate in 4/21 (19%), rituximab (RTX) in 1/21 (4.8%) and mycophenolate mofetil (MMF) in 1/21 (4.8%). We chose the immunosuppressive therapy via the same protocol used for NMOSD patients in our centre, starting with azathioprine as a first-line treatment due to limited access to MMF and RTX. Azathioprine was the first choice for all patients in the treatment group. Two patients who had relapses despite optimal azathioprine dosing were switched to RTX and/or MMF; four patients were switched from azathioprine to methotrexate due to side effects. In the treatment group, the median number of attacks dropped from 2.5 before treatment to 1 after treatment (p < 0.001; Figure 1 ). Remission during the preceding 2 years was achieved in 10/21 (48%) of the patients. In the patients who received acute treatment, intravenous methylprednisolone was used in 78 out of 101 (77%) attacks, and plasmapheresis was added to 23 of these.
Clinical outcomes
At the last visit, the median EDSS score was 2 (IQR 1.0;3.0) in the relapsing group and 1 (IQR 0.3;1.0) in the group with a single attack (p = 0.048). When EDSS was compared between nadir and the last follow-up, both the monophasic and relapsing group had achieved a significant recovery ( 
Longitudinal analysis of MOG-IgG
Longitudinal serum samples were obtained in all 31 MOG-IgG-positive patients at a median clinical follow-up of 65 months (IQR 39;103). The median number of samples obtained in the monophasic group was 3.5 (IQR 3.0;3.0), and the median number obtained in the relapsing group was 4 (IQR 4;4). The median time between clinical onset and acquisition of the first sample was 24 months (IQR 2;121). Only one sample was negative in the first analysis; this patient became positive during follow-up. The median times between sample acquisitions were as follows: first to second sample, 15 months (IQR 9;32); second to third, 12 months (IQR 7;26); third to fourth, 9 months (IQR 6;13) and fourth to fifth, 7 months (IQR 6;10). A total of 119 samples were collected and analysed for both MOG-IgG and AQP4-IgG. Double positivity was not observed. All patients had been tested before any treatment or at least 1 month after intravenous methylprednisolone (IVMP)/plasma exchange (PLEX).
All monophasic patients became MOG-IgG-negative within a median time of 25 months (IQR 24;24) after the first positive sample was acquired and subsequently remained persistently negative in samples collected during subsequent follow-up visits ( Figure  2) . The clinical features of the monophasic patients are shown in Table 3 . In all, 10 (43.5%) patients in the relapsing group were considered to be in remission at the last follow-up, and these patients had more negative samples than did those without clinical remission (p = 0.003). The median MOG-IgG titre was higher (mean = 9557.3, IQR = 2517.3;23022.7) among patients without clinical remission than among those who did not experience a relapse (mean = 1536, IQR 448;5120, p = 0.020). After immunosuppressive treatment, half of the MOG-IgG-positive patients had a seronegative result during the 2-year follow-up period (Wilcoxon paired test, p = 0.003).
Discussion
To the best of our knowledge, this is one of the longest prospective follow-up studies with MOG-IgGpositive patients and the largest study evaluating longitudinal MOG-IgG samples and clinical prognosis. Our findings suggest a close relationship between the persistence of MOG-IgG positivity during followup and the risk of further relapses in MONEM. However, the available literature data are limited, and some series have shown that clinical relapse can occur despite seronegative conversion. 10, 11 The discrepancies observed in the literature may be related to small sample sizes, as well as the types of treatment and follow-up durations.
The proportion of relapsing patients seems to increase with follow-up duration in MONEM. 1, 2, 4 In fact, the majority of our patients had a relapsing course in which recurrent ON was the predominant phenotype, confirming the findings of other series. 1, 4, 12, 13 In this study, we observed that every new attack of ON increased the probability of a subsequent new attack in patients with MONEM and that the risk of relapses in recurrent phenotypes was low after immunosuppressive therapy. However, we do not have a larger number of untreated relapsing patients in our study with whom to compare the treated patients. ON associated with MOG-IgG predominantly affects the intra-orbital and canalicular segments rather than the chiasm, consistent with previous reports. 14, 15 Although visual disability at nadir and permanent visual disability can occur in MONEM, good recovery is reported more frequently than poor recovery when compared with AQP4-IgG-positive NMOSD. 13, 16 We similarly found that EDSS and visual acuity significantly improved between nadir and the last visit.
In our evaluation of longitudinal serum samples, no double positivity for AQP4-IgG and MOG-IgG antibodies was observed, supporting the extremely low frequency of this finding in the literature. 17 In our series, no patients received a diagnosis of MS during follow-up, suggesting that MONEM is a demyelinating disease that is distinct from MS. Therefore, MOG-IgG most likely mediates a disease different from AQP4-IgG + NMOSD and MS in adults. 7 In the monophasic group, no patients received longterm immunosuppressive therapy after acute phase treatment, and MOG-IgG serum levels declined spontaneously in this population and subsequently remained negative throughout follow-up. All but one patient in this group became MOG-IgG negative within 25 months of clinical onset. Other series have similarly reported the disappearance of MOG-IgG in many monophasic patients. 5, 18 In a longitudinal study limited to paediatric patients for a period of up to 5 years, Prosbtel et al. reported declining MOG-IgG titres in monophasic patients, whereas patients with relapses had persistent fluctuations in MOG-IgG titres during the follow-up period. Among relapsing patients, a larger proportion of the negative samples were obtained and the titres were smaller in patients in clinical remission than in those with disease activity. Most of these patients received long-term immunosuppressive therapy, which was associated with a reduction in the number of new attacks and serum MOG-IgG positivity. Together, these data suggest that longitudinal follow-up of serum MOG-IgG levels may be useful for predicting the risk of new relapse and determining whether a patient may benefit from long-term immunosuppression. 17 This study has some limitations. In relapsing patients, disease duration was longer than the follow-up time because some patients were referred to our centre after the first attack, and it was therefore not possible to establish a relationship between a second attack and MOG-IgG titres in this subgroup. Patients with a single attack were followed since the first event, but they had a shorter follow-up period than the relapsing group; thus, future studies with a longer follow-up duration are required. Nevertheless, the follow-up period in the monophasic group was long enough to be higher than the median time to a second attack in the relapsing group. However, a strength of the present prospective study is that these data show that persistent seropositivity for MOG-IgG plays a significant role in discriminating patients who are likely to evolve relapses and disabling disease, indicating the usefulness of measuring MOG-IgG in clinical practice.
In conclusion, we found that persistent MOG-IgG positivity during follow-up examination strongly indicates a risk of subsequent relapse, and these patients should be treated with immunosuppressive drugs to lower this risk. In contrast, MOG-IgGpositive patients who seroconvert to a negative status after their first attack do not experience a relapse. These patients require acute treatment during attacks, but they may not benefit from long-term immunosuppressive therapy.
